Understanding the specific features that push a squamous cell carcinoma into a higher-risk category
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Squamous cell carcinoma (SCC) behaves differently from basal cell carcinoma in one important way: it has a real, if still overall low, chance of spreading to lymph nodes or, less often, to distant organs. Across all SCCs, that risk is roughly 2-5% for nodal spread — most people treated for SCC will never experience it. But that average number hides a wide range. A small, well-differentiated SCC on the trunk behaves almost nothing like a large, deeply invasive one on the ear, and dermatologists rely on a specific set of well-studied features to tell the two apart.
This guide walks through those features — tumor size and depth, differentiation, nerve and vessel involvement, location, and patient-level factors like immunosuppression — and explains how they're used to stratify risk and decide whether additional imaging or a lymph node evaluation is warranted. It also separates two things that get conflated: the risk of a tumor coming back where it was treated (local recurrence) versus the risk of it spreading elsewhere in the body (nodal or distant metastasis).
"SCC coming back" can mean two very different things, and it's worth keeping them separate. Local recurrence means the cancer regrows at or very near the site it was originally removed from — usually because microscopic cancer cells extended beyond what was visible or beyond the treatment margin. Nodal metastasis means cancer cells have traveled through the lymphatic system to nearby lymph nodes, most often in the neck, in front of the ear, or in the groin depending on the tumor's location. Distant metastasis — spread to the lungs, liver, bone, or elsewhere — is the least common outcome and typically follows nodal spread rather than happening independently.
These three outcomes share risk factors but aren't identical: a tumor can have a meaningfully elevated local recurrence risk without a correspondingly high metastatic risk, and vice versa. Your dermatologist or Mohs surgeon will typically discuss which of these your specific tumor's features place it at higher risk for, since it changes how closely you're followed. Our follow-up care guide covers what that monitoring schedule actually looks like.
National guidelines (NCCN in the US, similar frameworks in Europe) identify a specific set of "high-risk" and "very-high-risk" features on pathology and clinical exam. Having one or more of these doesn't mean spread has happened — it means your care team will likely recommend closer monitoring, a wider excision margin or Mohs surgery, and in some cases imaging.
Larger tumors carry more risk than smaller ones at every stage of assessment. Tumors greater than 4 cm are classified as very-high-risk regardless of other features.
How deep a tumor has grown matters as much as how wide it is. Invasion deeper than 6 mm, or growth beyond the subcutaneous fat layer into muscle or deeper structures, is a very-high-risk feature under NCCN criteria.
On pathology, cells are graded by how closely they still resemble normal squamous cells. Poorly differentiated tumors — cells that look markedly abnormal under the microscope — behave more aggressively and are an independently identified risk factor for lymph node spread in facial SCC specifically.
This means cancer cells are tracking along a nerve. It matters most when it involves a large-caliber nerve — 0.1 mm or larger in diameter, even if the nerve is unnamed — which NCCN classifies as very-high-risk and typically prompts MRI imaging to check for occult spread further along the nerve than what's visible on the skin.
Cancer cells found within small blood vessels or lymphatic channels on pathology indicate the tumor has a physical route to spread beyond the original site, and this is treated as a very-high-risk feature.
These "mask areas," along with other thin-skin, high-risk sites, carry elevated risk partly because thin tissue offers less of a barrier to deeper invasion. European consensus guidelines specifically flag tumors over 20 mm in these locations as high-risk. See our guide to SCC in high-risk locations for more on why these areas behave differently.
Desmoplastic SCC — a subtype where tumor cells are embedded in dense fibrous tissue — tends to invade more aggressively and is associated with higher rates of perineural invasion. A tumor that's grown noticeably over just weeks to a few months, rather than slowly over a year or more, is also treated as a warning sign independent of its size at any single visit.
This is one of the largest risk multipliers in all of dermatology. Solid organ transplant recipients face up to a 65- to 100-fold higher risk of developing SCC in the first place compared to the general population, driven by the long-term immunosuppressive medication needed to prevent organ rejection. Beyond that baseline increase in incidence, SCCs in this population are also managed more aggressively — with a lower threshold for imaging, sentinel node evaluation, and multidisciplinary review — because close surveillance and early biopsy are what keep outcomes for transplant recipients comparable to those of other high-risk patients. The same elevated vigilance applies to people on long-term immunosuppressive therapy for other reasons, such as chronic inflammatory disease or leukemia.
An SCC that has already come back once after treatment is inherently higher-risk than a new, previously untreated tumor of the same size — recurrence itself is evidence that the original treatment didn't fully clear the cancer, and recurrent tumors are statistically more likely to recur again or to spread than tumors treated successfully the first time.
Rather than treating every SCC the same way, dermatologists and Mohs surgeons use a formal risk stratification system — based on NCCN criteria in the US, closely aligned with AJCC staging — that sorts tumors into low-risk, high-risk, and very-high-risk categories using exactly the features above. Our staging and grading guide covers how that classification process works in more detail.
That category determines what happens next. Low-risk tumors are typically treated with standard excision and routine follow-up. High-risk and very-high-risk tumors may prompt a physical or ultrasound exam of the regional lymph nodes at diagnosis, baseline imaging (often MRI with contrast, especially when perineural invasion is suspected), a discussion of adjuvant radiation after surgery, and — for a subset of very-high-risk tumors without clinically palpable nodes — consideration of sentinel lymph node biopsy to check for microscopic spread that wouldn't otherwise be detected. None of this happens automatically for every SCC; it's specifically reserved for the tumors whose features put them in these higher categories.
Most people treated for squamous cell carcinoma will never see it come back or spread — the overall nodal metastasis rate of roughly 2-5% reflects that the majority of SCCs are lower-risk and highly curable with standard treatment. The exceptions are well-characterized: tumors that are large, deep, poorly differentiated, invading nerves or vessels, sitting in a mask area, or arising in someone who is immunosuppressed or has already had a recurrence.
Knowing which of these features apply to your specific tumor — and understanding why they change your monitoring plan — is what turns an abstract statistic into a concrete follow-up plan you and your doctor can act on together.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or Mohs surgeon about your personal risk category and follow-up plan.
Chat with our AI guide for personalized information about SCC recurrence and metastasis risk
Chat with the Navigator